Wnt/β-catenin signaling in cancers and targeted therapies
Open accessThe DOI matches its Crossref record; 468 of the 468 references it cites were found in a registry or an index.
Abstract
Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals. Aberrant activation of Wnt/β-catenin signaling is tightly linked with the increment of prevalence, advancement of malignant progression, development of poor prognostics, and even ascendence of the cancer-associated mortality. Early experimental investigations have proposed the theoretical potential that efficient repression of this signaling might provide promising therapeutic choices in managing various types of cancers. Up to date, many therapies targeting Wnt/β-catenin signaling in cancers have been developed, which is assumed to endow clinicians with new opportunities of developing more satisfactory and precise remedies for cancer patients with aberrant Wnt/β-catenin signaling. However, current facts indicate that the clinical translations of Wnt/β-catenin signaling-dependent targeted therapies have faced un-neglectable crises and challenges. Therefore, in this study, we systematically reviewed the most updated knowledge of Wnt/β-catenin signaling in cancers and relatively targeted therapies to generate a clearer and more accurate awareness of both the developmental stage and underlying limitations of Wnt/β-catenin-targeted therapies in cancers. Insights of this study will help readers better understand the roles of Wnt/β-catenin signaling in cancers and provide insights to acknowledge the current opportunities and challenges of targeting this signaling in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The inactivation of GSK3β disrupts the integrity and function of the destruction complex, thereby preventing β-catenin phosphorylation. As a result, unphosphorylated, stable β-catenin accumulates in the cytoplasm, translocates to the nucleus, and activates the transcription of its target genes, including c-Myc and Cyclin D1 [35, 46, 47, 52–55].”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 401–468 of 468
Guo, S., Tan, L., Pu, W., Wu, J., Xu, K., Wu, J., Li, Q., Ma, Y., Xu, J., Li, J., et al. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-5 · Cited by 33 · cited 1×
“The DNA methylation of Apc promoter is closely associated with various cancers, like lung cancer and prostatic cancer.(145,146) The methylation reduces the normal expression of Apc in cancers, resulting in abnormal activation of the Wnt/β-catenin signaling pathway.”
BackgroundTang, L., Zhu, H., Yang, X., Xie, F., Peng, J., Jiang, D., Xie, J., Qi, M., & Yu, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152012 · Cited by 33
Sun, Y., Wang, W., & Zhao, C. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504020x16014648664459 · Cited by 33
APC Mutations Are Not Confined to Hotspot Regions in Early-Onset Colorectal Cancer
Aitchison, A., Hakkaart, C., Day, R. C., Morrin, H. R., Frizelle, F., & Keenan, J. I. (2020) · Cancers · doi:10.3390/cancers12123829 · Cited by 33 · cited 13×
“The constitutive activation form of β-catenin, the exon 3 mutations, is believed to regulate the Signal Transduction and Targeted Therapy (2021) 6:307 genesis of hereditary non-polyposis CRC.208 In CRC, there are several mutations of β-catenin, leading to abnormally activated Wnt/β-catenin signaling.209 The mutations…”
BackgroundInfluentialAXIN2 Polymorphisms and Their Association with Colorectal Cancer in Mexican Patients
Reynoso, M. A. R., Arredondo-Valdez, A. R., Wence-Chávez, L. I., Barros‐Núñez, P., Gallegos‐Arreola, M. P., Flores-Martínez, S. E., & Sánchez‐Corona, J. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2016.0026 · Cited by 32
Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival
Varghese, R. T., Young, S., Pham, L., Liang, Y., Pridham, K. J., Guo, S., Murphy, S. F., Kelly, D. F., & Sheng, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-31864-x · Cited by 32 · cited 1×
“IC261 is a selective, ATP-competitive CK1 inhibitor that has shown its high efficiency in handling CRC and glioblastoma cells.(352,353) Not only that, IC261 has alternatively biological effects that may lead to the death of cancer cells independent of inhibiting the canonical Wnt pathway.”
BackgroundBendell, J. C., Eckhardt, G. S., Hochster, H. S., Morris, V. K., Strickler, J. H., Kapoun, A. M., Wang, M., Xu, L., McGuire, K., Dupont, J., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32668-5 · Cited by 31 · cited 1×
“RSPO3/mAb OMP-131R10 Bendell et al.(314) CRC, ovarian cancer”
BackgroundCha, Y., He, Y., Ouyang, K., Xiong, H., Li, J., & Yuan, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.9480 · Cited by 31
TCF4 Is a Molecular Target of Resveratrol in the Prevention of Colorectal Cancer
Jeong, J. B., Lee, J., & Lee, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510411 · Cited by 31
Cao, X., Hong, Y., Eu, K. W., Loi, C. T., & Cheah, P. Y. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00842.x · Cited by 30 · cited 1×
“Mutations of Apc can cause familial adenomatous polyposis (FAP), which is also the major hereditary carcinogenic factor in CRC progression.(129,130) A study showed that around 72% of Apc mutations were detected spreading throughout the Apc gene in early-onset CRC.”
BackgroundChon, H. J., Lee, Y., Bae, K. J., Byun, B. J., Kim, S. A., & Kim, J. (2016) · Amino Acids · doi:10.1007/s00726-016-2214-3 · Cited by 30
Sugano, T., Masuda, M., Takeshita, F., Motoi, N., Hirozane, T., Goto, N., Kashimoto, S., Uno, Y., Moriyama, H., Sawa, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01162-3 · Cited by 30 · cited 1×
“Their latest discovery was NCB-0846, which inhibited the growth in a variety of patient-derived CRC xenografted tumors,(375) and abrogated the EMT of DLD-1, HCT-116, and A549 cell lines.(376,377) As ATP-competitive inhibitors, NCB series drugs may also have inhibitory effects on other kinases.”
BackgroundWang, Z., Tacchelly‐Benites, O., Yang, E., Thorne, C. A., Nojima, H., Lee, E. N., & Ahmed, Y. F. (2016) · Genetics · doi:10.1534/genetics.115.183244 · Cited by 30 · cited 1×
“The enzymes bind and then PARylate Axins, utterly, the Axins are ubiquitylated and degraded.(174,175) Additionally, researches showed that tankyrase enhanced Wnt/β-catenin signaling.”
BackgroundRole of Wnt3a in the pathogenesis of cancer, current status and prospective
Pashirzad, M., Fiuji, H., Khazei, M., Binabaj, M. M., Ryzhikov, M., Shabani, M., Avan, A., & Hassanian, S. M. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04895-4 · Cited by 30 · cited 3×
“Wnt3 is a homologous gene of Wnt3a, and the similarity is up to 84.2% total amino-acid identity in humans.60 The level of Wnt3 mRNA was obviously upregulated in primary breast and rectal cancer.60 Wnt3 plays a cacoethic role in multiple cancers, such as CRC,61 breast cancer,62,63 NSCLC,64,65 and prostate cancer.66 Spe…”
BackgroundInfluentialChoi, A.-R., Park, J.-R., Kim, R., Kim, S., Cho, S., Jung, J., & Nam, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.120 · Cited by 30 · cited 1×
“Conversely, overexpression of Wnt1 promoted the growth of cancers.(48,49) Therapeutically, Blocking Wnt1 has been found to strengthen the apoptosis of colorectal cancer (CRC) cells via the utilization of Wif1, Wnt1-specific siRNAs, and neutralizing antibodies.”
BackgroundQualtrough, D., Rees, P., Speight, B., Williams, A. C., & Paraskeva, C. (2015) · Cancers · doi:10.3390/cancers7030867 · Cited by 30 · cited 1×
“For instance, cyclopamine, as an inhibitor of Shh signaling, postpones the invasion of CRC by suppressing β-catenin–Tcf transcriptional activity.(270)”
BackgroundThymine DNA glycosylase promotes transactivation of β-catenin/TCFs by cooperating with CBP
Jia, Y., Nie, F., Du, A., Chen, Z., Qin, Y., Huang, T., Song, X., & Li, L. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju014 · Cited by 29 · cited 1×
“CBP promotes the transactivation of β-catenin/Tcf cooperating with thymine DNA glycosylase.(221) In addition, the transcription complex recruits p300/CBP,(222,223) Bcl9,(224) Pontin522,(225) Reptin52,(225) Brg-1,(226,227) Mllt/Af10-Dot1,(228) SOX10,(229) p68/p72,(230) βTrCp1/Fbw1a,(231) FOXM1, and yes-associated prote…”
BackgroundWu, D., Zhang, Y., Huang, J., Fan, Z., Shi, F., & Wang, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.032 · Cited by 29
Lee, Y., Jung, J.-I., Park, K.-Y., Kim, S. A., & Kim, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17056 · Cited by 29 · cited 1×
“Also, the NCB-0005 cooperated with the RTK inhibitor dovitinib to impede the growth of multiple myeloma cells.(374) Their latest discovery was NCB-0846, which inhibited the growth in a variety of patient-derived CRC xenografted tumors,(375) and abrogated the EMT of DLD-1, HCT-116, and A549 cell lines.”
BackgroundLiu, Z., Li, H., Liu, J., Wu, M., Chen, X.-Y., Liu, L., & Wang, Q. (2017) · Oncology Letters · doi:10.3892/ol.2017.6458 · Cited by 29
Xu, Y., Li, H., Huang, C., Zhao, T., Zhang, H., Zheng, C., Ren, H., & Hao, J. (2015) · Medical Oncology · doi:10.1007/s12032-015-0513-2 · Cited by 28
Villota, H., Röthlisberger, S., & Pedroza-Díaz, J. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1884730 · Cited by 27 · cited 1×
“Moreover, silibinin, an extract from the milk thistle seeds, also showed its potentiality in preventing tumorigenesis in a preclinical model.(402,403) In addition to natural products, many FDA-approved drugs have expanded their indications to crosstalk with Wnt/β-catenin signaling.”
BackgroundFeasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma
Sekita, T., Yamada, T., Kobayashi, E., Yoshida, A., Hirozane, T., Kawai, A., Uno, Y., Moriyama, H., Sawa, M., Nagakawa, Y., et al. (2020) · Cancers · doi:10.3390/cancers12051258 · Cited by 26 · cited 1×
“In addition to CRC, inhibitory effects of NCB drugs have also been reported in other tumors.(378,379) Inhibitors targeting β-catenin–-Lef/Tcf complex.”
BackgroundRottlerin as a novel chemotherapy agent for adrenocortical carcinoma
Zhu, Y., Wang, M., Zhao, X., Zhang, L., Wu, Y., Wang, B., & Wei-lie, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15221 · Cited by 26
Frizzled-10 and cancer progression: Is it a new prognostic marker?
Scavo, M. P., Fucci, L., Caldarola, L., Mangia, A., Azzariti, A., Simone, G., Gasparini, G., & Krol, S. (2017) · Oncotarget · doi:10.18632/oncotarget.23159 · Cited by 25 · cited 1×
“Besides, Fzd10 plays an important positive role in various cancers, at least in CRC development, but the level of Fzd10 is down in metastatic cancers.(100) The Fzd10 expression may be a prognostic marker in CRC,(100) and the same is true in synovial sarcoma.”
BackgroundInhibition of cyclin D1 gene transcription by Brg-1
Rao, M., Casimiro, M. C., Lisanti, M. P., D’Amico, M., Wang, C., Shirley, L. A., Leader, J. E., Liu, M., Stallcup, M. R., Engel, D. A., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5446 · Cited by 25
Self-citationLiu, M., Hu, Y., Lu, S., Lu, M., Li, J., Hai-min, C., Jia, H., Zhou, M., Ren, F., & Zhong, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.40960 · Cited by 25 · cited 2×
“IC261 is a selective, ATP-competitive CK1 inhibitor that has shown its high efficiency in handling CRC and glioblastoma cells.(352,353) Not only that, IC261 has alternatively biological effects that may lead to the death of cancer cells independent of inhibiting the canonical Wnt pathway.”
BackgroundAbdelmaksoud‐Dammak, R., Miladi-Abdennadher, I., Triki, M., Khabir, A., Charfi, S., Ayadi, L., Frikha, M., Sellami‐Boudawara, T., & Mokdad‐Gargouri, R. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.01.001 · Cited by 24 · cited 2×
“Interestingly, HIF2α binds to the β-catenin–Tcf complex at a different site from HIF1α to recruit p300 and then enhances Wnt/β-catenin signaling.(210) The synergistic actions of HIF2α and β-catenin increase the proliferation of renal cell carcinoma cells.”
BackgroundWnt receptor Frizzled 8 is a target of ERG in prostate cancer
Chakravarthi, B. V. S. K., Chandrashekar, D. S., Balasubramanya, S. A. H., Robinson, A. D., Carskadon, S. L., Rao, U., Gordetsky, J., Manne, U., Netto, G. J., Sudarshan, S., et al. (2018) · The Prostate · doi:10.1002/pros.23704 · Cited by 24 · cited 3×
“Prostate cancer metastasis is related to ERG inducing Fzd8 upregulation.(99) Besides, Fzd10 plays an important positive role in various cancers, at least in CRC development, but the level of Fzd10 is down in metastatic cancers.”
BackgroundInfluentialZHANG, C., Li, C., Chen, X., Zhou, Y., Yin, B., Ni, R., Zhang, Y., & Liu, J. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1697-z · Cited by 24 · cited 1×
“For instance, Dvl2 was overexpressed in HCC and reported to link with poor prognosis.(367) In comparison to normal adult bronchial/alveolar epithelial and Wnt/β-catenin signaling in cancers and targeted.”
BackgroundThe inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by sulindac.
Tai, W.-P., Hu, P., Wu, J., & Lin, X.-C. (2014) · PubMed · doi:10.1700/1430.15823 · Cited by 24
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Kierulf-Vieira, K. S., Sandberg, C. J., Waaler, J., Lund, K., Skaga, E., Mikkelsen, B., Panagopoulos, I., Brandal, P., Krauss, S. J. K., Langmoen, I. A., et al. (2020) · Cancers · doi:10.3390/cancers12061630 · Cited by 24 · cited 1×
“As an adjuvant, G007-LK can also enhance the sensitivity of glioma stem cells to a chemo drug temozolomide and CRC cells to PI3K/EGFR inhibitors.(339,340) As mentioned above, IWR compounds were defined based on their anti-Wnt pathway activities in a phenotypic screening assay.”
BackgroundGao, X., Zacharek, A., Grignon, D. J., Liu, H., Sakr, W., Porter, A. T., Chen, Y. Q., & Kv, H. (1995) · International Journal of Oncology · doi:10.3892/ijo.6.1.111 · Cited by 24
Dual Roles for Membrane Association of Drosophila Axin in Wnt Signaling
Wang, Z., Tacchelly‐Benites, O., Yang, E., & Ahmed, Y. F. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006494 · Cited by 23 · cited 1×
“Additionally, researches showed that tankyrase enhanced Wnt/β-catenin signaling.(176,177) A series of studies further proved that tankyrase could suppress cancer development via inhibiting the Wnt/β-catenin signaling pathway.”
BackgroundDoubravská, L., S̆ímová, S., C̆ermák, L., Valenta, T., Kořínek, V., & Anděra, L. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0191-z · Cited by 23
Tian, X., Hou, W., Bai, S., Fan, J., Tong, H., & Xu, H. J. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2406 · Cited by 23 · cited 1×
“XAV939 and RNAi-Tnks1 inhibited the stemness and migration of cancer stem cells and accelerated cell apoptosis in neuroblastoma by attenuating the abnormal status of Wnt/β-catenin signaling.(332,333) XAV939 and IWR, the inhibitors of Tnks, repressed the growth of lung cancer and reduced tumorigenesis.”
BackgroundOno, M., Lai, K. K. Y., Wu, K., Nguyen, C., Lin, D. P., Murali, R., & Kahn, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200714 · Cited by 22
WANG, B., ZOU, Q., Sun, M., Chen, J., Wang, T., Bai, Y., Chen, Z., Chen, B., & Zhou, M. (2014) · Oncology Reports · doi:10.3892/or.2014.3476 · Cited by 22 · cited 1×
“In addition, WNT-C59 can reverse the resistance of trichostatin A in human pancreatic cells.(297) However, when administrated at 10mg/kg/d for 7 or 21 days, bone loss was observed in mice.”
BackgroundBu, Q., Li, Z., Zhang, J., Xu, F., Liu, J., & Liu, H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.791756 · Cited by 21
Pratheeshkumar, P., Divya, S. P., Parvathareddy, S. K., Alhoshani, N. M., Al-Badawi, I. A., Tulbah, A. M., Al‐Dayel, F., Siraj, A. K., & Al-Kuraya, K. S. (2017) · Oncotarget · doi:10.18632/oncotarget.23338 · Cited by 21
Utilizing ethacrynic acid and ciclopirox olamine in liver cancer
Al‐Dali, A., Weiher, H., & Schmidt‐Wolf, I. G. H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9472 · Cited by 21
Hui, H., Wu, N., Wu, M., Liu, Y., Xiao, S., & Zhang, M. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000307 · Cited by 20
MicroRNA-214 targets Wnt3a to suppress liver cancer cell proliferation
Yang, Y., Zhao, Z., Hou, N., Li, Y., Wang, X., Wu, F., Sun, R., Han, J., Sun, H., Song, T., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7483 · Cited by 20 · cited 1×
“For liver cancers, targeting Wnt3a by miRNA-195 and miRNA‐214 presented the possibility of cancer management.(78,79)”
BackgroundThe CK1α Activator Pyrvinium Enhances the Catalytic Efficiency (kcat/Km) of CK1α
Shen, C., Li, B., Astudillo, L., Deutscher, M. P., Cobb, M. H., Capobianco, A. J., Lee, E. N., & Robbins, D. J. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00891 · Cited by 19 · cited 1×
“This activation may be achieved by allosteric regulation, thereby improving the catalytic ability of CK1 without affecting the binding of substrates.(357) Although pyrvinium also showed inhibitory ability in other Wnt/β-catenin signaling-driven tumor cell lines (SUM-149/SUM-159,(358) and A2278(359)), its bioavailabili…”
BackgroundThe anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1
Benad, P., Rauner, M., Rachner, T. D., & Hofbauer, L. C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.006 · Cited by 19
Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling
Galli, L. M., Zebarjadi, N., Li, L., Lingappa, V. R., & Burrus, L. W. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.07.028 · Cited by 19
Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228 Impairs Tumor Growth of Colon Cancer
KIM, J. Y., PARK, G., KRISHNAN, M., HA, E., & CHUN, K.-S. (2019) · Anticancer Research · doi:10.21873/anticanres.13514 · Cited by 18
The F-box Protein β-TrCp1/Fbw1a Interacts with p300 to Enhance β-Catenin Transcriptional Activity
Kimbrel, E. A., & Kung, A. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901248200 · Cited by 18
Novel strategies for comprehensive mutation screening of the APC gene
Wachsmannová, L., Mego, M., Števurková, V., Zajac, V., & Čierniková, S. (2017) · Neoplasma · doi:10.4149/neo_2017_303 · Cited by 17 · cited 1×
“Over 700 somatic mutations of Apc resulted in various types of cancers by truncating Apc protein that was dependent on nonsense (34%) or frameshift mutation (62%).(127,128) Mutations of Apc can cause familial adenomatous polyposis (FAP), which is also the major hereditary carcinogenic factor in CRC progression.”
BackgroundIC261 suppresses progression of hepatocellular carcinoma in a casein kinase 1 δ/ε independent manner
Yuan, F., Li, D., Guo, M., Fang, T., Sun, J., Qi, F., Rao, Q., Zhao, Z., Huang, P., Yang, B., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.105 · Cited by 16 · cited 5×
“In an in vitro study, IC261 induced centrosome fragmentation during mitosis independent of CK1δ.(355) Other CK1 inhibitors include PF670 and PF480 that do not kill cancer cells.”
BackgroundInfluentialWnts grasp the WIF domain of Wnt Inhibitory Factor 1 at two distinct binding sites
Kerekes, K., Bányai, L., & Patthy, L. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.08.031 · Cited by 16
Liu, C., Witt, L., Ianes, C., Bischof, J., Bammert, M.-T., Baier, J., Kirschner, S., Henne‐Bruns, D., Xu, P., Kornmann, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246184 · Cited by 15 · cited 2×
“However, as IWPs have a similar structure to certain CK1 inhibitors, much research have proposed the effects on CK1 isoform suppression of IWPs.(302,303) IWP-2 and IWP-4 inhibited the proliferation of various cancer cells via antagonizing Porc and CK1α.”
BackgroundSantis, S. D., Verna, G., Serino, G., Armentano, R., Cavalcanti, E., Liso, M., Dicarlo, M., Coletta, S., Mastronardi, M., Lippolis, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082972 · Cited by 14
Streptonigrin inhibits β-Catenin/Tcf signaling and shows cytotoxicity in β-catenin-activated cells
Park, S., & Chun, S. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.06.023 · Cited by 13
The Association Between AXIN2 Gene Polymorphisms and the Risk of Breast Cancer in Chinese Women
Dai, J., Gao, H., Xue, J., Lin, W., & Zheng, L. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0309 · Cited by 13
Du, Y., Liu, X., & Shan, B. (2009) · PubMed · Cited by 13
Xing, Z., Wang, H.-Y., Su, W.-Y., Liu, Y., Wang, X.-X., Zhan, P., Lv, T.-F., & Song, Y.-G. (2018) · PubMed · doi:10.26355/eurrev_201803_14474 · Cited by 12 · cited 1×
“knockdown of Wnt3 could increase drug sensitivity.(64,65) In prostate cancer, inhibiting Wnt3 signaling by the deficiency of trophinin-associated protein attenuated the cancer growth.”
BackgroundChang, L.-C., Chen, T., Chen, S.-J., Chen, C., Lee, C.-C., Wu, S., Yen, Y., Huang, H., & Lin, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6622 · Cited by 11
Transmembrane protein 64 modulates prostate tumor progression by regulating Wnt3a secretion
Moon, Y. H., Lim, W., & Jeong, B. (2019) · Oncology Letters · doi:10.3892/ol.2019.10324 · Cited by 11 · cited 1×
“Therapeutically, in prostate cancers, targeting Wnt3a through Traf6 either Tmem64 restrained tumor development.(76,77) For liver cancers, targeting Wnt3a by miRNA-195 and miRNA‐214 presented the possibility of cancer management.”
BackgroundAxin2+ endometrial stem cells: the source of endometrial regeneration and cancer
Syed, S. M., & Tanwar, P. S. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1729681 · Cited by 10
Teneggi, V., NG, M. M., Tan, D. S. P., Subbiah, V., Weekes, C. D., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00310-0 · Cited by 10
beta-catenin gene mutation in invasive ductal breast cancer.
Kızıldağ, S., Zengel, B., Vardar, E., & Sakızlı, M. (2008) · PubMed · Cited by 9
Teneggi, V., Ng, M., Tan, D. S., Subbiah, V., Weekes, C., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw579.004 · Cited by 8 · cited 1×
“Unfortunately, the absence of Apc is likely to induce a Wnt ligand-independent signaling, so tumors with Apc LoF mutations may be resistant to Porc inhibitors.(279) And Picco et al.”
BackgroundMutation of β-catenin in a radiation and estrogen breast cancer model
ROY, D., & Calaf, G. M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2722 · Cited by 6
Komatsu, Y., Takashima, A., Denda, T., Gamoh, M., Iwanaga, I., Shimodaira, H., Nakamura, M., Yamaguchi, T., Takahashi, H., Kobayashi, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.001 · Cited by 6
Gowrikumar, S., Ahmad, R., Uppada, S. B., Washington, M. K., Shi, C., Singh, A. B., & Dhawan, P. (2019) · Oncogene · doi:10.1038/s41388-019-0864-9 · Cited by 6
Nakata, D., Koyama, R., Nakayama, K., Kitazawa, S., Watanabe, T., & Hara, T. (2017) · The Prostate · doi:10.1002/pros.23351 · Cited by 5
Fiskus, W. C., Smith, J. A. I., Mudunuru, U., Hembruff, S. L., Reyes, R., Abhyankar, S., McGuirk, J. P., Aljitawi, O. S., Ganguly, S., Horrigan, S. K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c144 · Cited by 3
Research works printed but not linked: 4
- Schwarz-Romond T The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization Nat. Struct. Mol. Biol. 2007 14 484 492 10.1038/nsmb1247 17529994 · DOI · Paper page
- Hoey, T. (ed.) Development of FZD8-Fc (OMP-54 F28), aWnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency. Presented at AACR Annual Meeting; 2013 April; Washington DC (2013).
- OncoMed Pharmaceuticals, Inc. A phase 1b dose escalation study of vantictumab (OMP-18R5) in combination with nab-paclitaxel and gemcitabine in patients with previously untreated stage IV pancreatic cancer. NCT02005315, 18R5-003R5. PMC7211194 31338636
- OncoMed Pharmaceuticals, Inc. A phase 1b dose escalation study of OMP-54F28 in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. NCT02092363, 54F28-003. PMC7397408 31174889
Cited by
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Research progress of glutathione peroxidase family (GPX) in redoxidation
Pei, J., Pan, X., Wei, G., & Hua, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147414 · Cited by 617
“In the Wnt pathway, the key step of the Wnt pathway is the binding of the Wnt protein to the Frizzled receptor, and the nuclear redox protein (NRX) blocks Disheveled (DVL) and plays a negative regulatory role in the Wnt pathway (Yu et al., 2021).”
Background(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Self-citationWnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“Consequently, extensive research has demonstrated the ability of rosmantuzumab to impede self-renewal and differentiation processes in acute myeloid leukemia cells within PDX models, while simultaneously preserving the normal physiological function of hematopoietic stem cells [347].”
BackgroundRole of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“Specifically, FadA binds to E-cadherin on the membrane, leading to the phosphorylation and internalization of E-cadherin, which is accompanied by increased β-catenin release and translocation into the nucleus due to the degradation of the E-cadherin/ β-catenin complex, resulting in the aberrant activation of Wnt signa…”
Background
Metadata
- Authors
- Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Ye, Ling
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-08-30
- Volume
- 6
- Issue
- 1
- Pages
- 307-307
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8403677
- OpenAlex
- W3198051187
- Cited by
- 734
- References
- 468
- Citations by year
- 2026: 106 · 2025: 234 · 2024: 200 · 2023: 139 · 2022: 53 · 2021: 2
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81825005)
- State Key Laboratory of Oral Disease
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- Wnt/β-catenin signaling, cancer, targeted therapy, aberrant signaling, malignant progression, prognosis, clinical translation, treatment resistance
- MeSH terms
- Humans, Neoplasm Proteins, Neoplasms, Wnt Proteins, beta Catenin, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.